ReviewCurrent opinion in immunology2013
Vaccine strategies to enhance immune responses in the aged.
Review in Current opinion in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.BMC infectious diseases · 2014Trial
- A n-heneicosane solid emulsion as a single-dose subunit vaccine elicits broad and durable immune responses in an aged and a Pox virus model.International journal of pharmaceutics: X · 2026Article
- Pre-Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS-CoV-2 Inactivated Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Editorial: Innate immune responses to SARS-CoV-2 in infected and vaccinated individuals.Frontiers in immunology · 2023Article
- Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination.Frontiers in immunology · 2022Article
- Network Topology of Biological Aging and Geroscience-Guided Approaches to COVID-19.Frontiers in aging · 2021Article
- New MoDC-Targeting TNF Fusion Proteins Enhance Cyclic Di-GMP Vaccine Adjuvanticity in Middle-Aged and Aged Mice.Frontiers in immunology · 2020Article
- Study of the Immune Response in the Elderly: Is It Necessary to Develop a Vaccine againstJournal of aging research · 2019Review
- Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.Frontiers in immunology · 2019Review
- Attrition of T Cell Zone Fibroblastic Reticular Cell Number and Function in Aged Spleens.ImmunoHorizons · 2018Article
- Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.Frontiers in immunology · 2018Article
- Interventions to restore appropriate immune function in the elderly.Immunity & ageing : I & A · 2018Review
- Innate immune responses in the ageing lung.Clinical and experimental immunology · 2017Review
- Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination.Frontiers in immunology · 2016Article
- Loss of Phagocytic and Antigen Cross-Presenting Capacity in Aging Dendritic Cells Is Associated with Mitochondrial Dysfunction.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- HIV infection Worsens Age-Associated Defects in Antibody Responses to Influenza Vaccine.The Journal of infectious diseases · 2015Article
- KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The elderly population is more susceptible to infections with higher risks of morbidity and mortality. This is caused by the accumulation of immune defects with aging. The best way to protect people against infections is vaccination. Unfortunately, the same immune defects that render the elderly susceptible to infectious diseases also prevent the development of protective immunity following immunization. A good example of this is the influenza vaccine that only protects between 40 and 60% of the vaccinees over 65 years. In the past decade, tremendous efforts have been put toward improving the influenza vaccine for the elderly. We therefore use this example to present various strategies employed to overcome these age-associated immune defects and hence make vaccines more efficacious for the aged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.